A Study in Subjects With Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects With Moderate Atopic Dermatitis
Sponsor: Ralexar Therapeutics, Inc.
A PHASE2 clinical study on Atopic Dermatitis and Eczema, Atopic, this trial is completed. The trial is conducted by Ralexar Therapeutics, Inc. and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jul 2017 — Oct 2017 [monthly]
Recruiting PHASE2
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ralexar Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .